Novo Nordisk says its insulin pump secures EMA marketing authorisation
pharmafile | June 28, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | EMA, Novo Nordisk, insulin pump, marketing, product launch
Diabetes drugmaker Novo Nordisk (NYSE: NYO) said it has secured European Medicines Agency (EMA) marketing approval for its insulin pump.
The product mylife YpsoPump will be used with prefilled pump cartridge NovoRapid PumpCart, the company said.
Christian Kanstrup, senior vice president, marketing, medical affairs and stakeholder engagement at Novo Nordisk, said: “Our partnerships with Ypsomed and Roche Diabetes Care enable us to offer new options designed to simplify insulin pump therapy for people living with diabetes and the healthcare professionals who manage their care.”
NovoRapid PumpCart contains NovoRapid (insulin aspart), a rapid-acting insulin from Novo Nordisk, and is a 1.6 ml prefilled pump cartridge specifically designed to make insulin pump therapy more convenient for some people with diabetes and the healthcare professionals caring for them.
Mark Evans, lecturer and honorary consultant in medicine at the University of Cambridge, said: “Insulin pump therapy can be an effective option for helping some people with diabetes, particularly those living with type 1 diabetes, however, operating a traditional insulin pump, and manually filling the insulin reservoir, can be complex and time-consuming. Given these factors, and the burden put upon health systems to train patients to use traditional pumps, efforts to simplify the process are truly welcomed.”
An insulin pump delivers insulin from a reservoir inside the pump to a patient’s body using an infusion set and a tiny cannula.
Anjali Shukla
Related Content
Baxter expands US portfolio with new injectables
Baxter International has announced the continued expansion of its pharmaceuticals portfolio with the launch of …
CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
EC approves Pfizer’s Prevenar 20 to protect paediatric patients against pneumococcal disease
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Prevenar 20, …
